4月1日,根据英国《金融时报》的报道,碧迪医疗已经开始与一些竞争对手就出售其生命科学业务进行谈判。今年2月6日,碧迪医疗在其官方网站上宣布,董事会一致授权管理层执行一项计划,将生物科学和诊断解决方案业务进行拆分。此举旨在加强战略聚焦、增加增长型投资与资本配置,从而为股东创造更高的价值。扩展阅读:正式官宣!碧迪医疗将拆分其生命科学与诊断业务自宣布分拆计划以来,该公司股价已下跌约7.5%。2024年,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.